Author: pr-moritz
Last saved by: Roland Birkhoff
Company: Bayer
Document comments: V-2024-03-05

Bayer to Present New Phase III Data for Gadoquatrane and Advancements of Radiology Portfolio at ECR 2026
•	Detailed data from pivotal Phase III program for investigational low-dose MRI contrast agent gadoquatrane across various clinical settings 
•	Focus on abdominal and cardiac MRI, magnetic resonance angiography (MRA), new analysis from Phase II and III data in central nervous system (CNS) imaging, as well as pharmacokinetics data
•	Data‑driven solutions and injector technologies on display to improve speed, connectivity and workflow efficiency

Berlin, January 26, 2026 – Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European Congress of Radiology (ECR) taking place from March 4-8, 2026, in Vienna, Austria. The focus will be on progress in the development pipeline for contrast agents and injectors as well as data-driven connectivity solutions designed to shape smarter workflows and support more informed decisions in radiology.

Bayer’s scientific sessions will provide new insights from the clinical development program for gadoquatrane, an investigational low-dose macrocyclic gadolinium-based contrast agent for contrast-enhanced magnetic resonance imaging (MRI). Several Phase III sub-group data will be presented, introducing the efficacy and safety of gadoquatrane in abdominal and cardiac MRI, magnetic resonance angiography (MRA), as well as new analysis from Phase II and Phase III studies in central nervous system (CNS) imaging and pharmacokinetics data. Across the clinical development program, gadoquatrane was investigated at a gadolinium dose of 0.04 mmol Gd/kg body weight. This represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. 

These sessions follow the announcement of positive topline data for all studies of the pivotal Phase III program QUANTI in 2025. Bayer has submitted applications for marketing authorization of gadoquatrane in markets around the world, including Japan, the U.S., the EU, and China, with more markets to follow in the next months. 

“We are delighted to join this year’s European Congress of Radiology, a premier global forum for us to engage with the community as a place where scientific exchange, education, collaboration and innovation converge to improve patient care,” said Nelson Ambrogio, President Radiology, Bayer. “As a committed partner to the radiology community and a leader in the field, Bayer is proud to showcase cutting‑edge science, present expert‑led symposia and advance technologies that help clinicians in their daily work. We look forward to continuing our support of the radiology community, striving to translate knowledge into better outcomes for patients worldwide.”

“ECR 2026 is driven by the belief that scientific progress in radiology depends on open exchange and strong collaboration,” stated Minerva Becker, ECR 2026 Congress President. “The congress brings together leading experts and innovative industry partners to advance research and translate innovation into clinical practice. Contributions such as Bayer’s, grounded in robust clinical science and technological development, highlight the value of partnership in shaping the future of radiology for patient benefit.”

Gadoquatrane-related sessions at ECR 2026

RPS 1611 – Neuroimaging: Innovation in Techniques and Contrast Agents
March 6, 16:00 - 17:30 CET
•	Gadoquatrane Demonstrates Similar Pharmacokinetics and Imaging Compared to Other Macrocyclic Extracellular GBCAs in Phase 2 and 3 CNS CE-MRI Studies
•	Population PK Modeling of Gadoquatrane: Supporting Regulatory Submission for Use in Patients of All Ages
•	Rationales for Non-standard GBCA Dosing – Low? – High? – When? & Why? A Literature-based Study

CTiR 18 – Clinical Trials in Radiology: Cardiac, Gastrointestinal and Interventional Studies
March 7, 09:30 - 11:00 CET
•	Subgroup Analysis of Cardiac MRI in a Phase 3 Trial Investigating Safety and Efficacy of Gadoquatrane for Low-dose Contrast-enhanced MRI of the Body

POS™ PULSE – Presenting Unique Live Science and Education
March 4, 14:00 CET
•	Subgroup Analysis of Abdominal MR Imaging in a Phase 3 Trial Investigating Safety and Efficacy of Gadoquatrane for Low-dose Contrast-enhanced MRI of the Body

RPS 415 – Technical innovations in Vascular Imaging
March 4, 13:00 - 14:30 CET
•	In Vitro and In Vivo Stability Assessment of the Investigational, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane
•	One-year Follow-up of Gadolinium Presence and Distribution: Evaluation of the Novel, High-relaxivity Contrast Agent Gadoquatrane 

Poster EPOS Radiologist (scientific)
•	Gadoquatrane for Contrast-Enhanced MR-Angiography, 60% Reduced Gadolinium Dose Contrast Agent
#23208
•	Pharmacokinetics of Gadoquatrane 
#13729

About Bayer in Radiology 
Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions. In 2024, Bayer’s radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including in molecular imaging and other promising fields.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

About the European Congress of Radiology
The ECR is the annual meeting of the European Society of Radiology (ESR), which represents more than 149,000 members from 188 countries worldwide. The ECR is one of the largest medical congresses in the world, attracting thousands of congress participants each year. With hundreds of companies showcasing their products at its technical exhibition, it is also one of the largest medical exhibitions in Europe.

Contact for media inquiries:
Victoria Vigener, phone +49 151 23438911
Email: victoria.vigener@bayer.com

Find more information at https://pharma.bayer.com/
Follow us on LinkedIn: Bayer | Pharmaceuticals
Follow us on Twitter: @BayerPharma

vig	(2025-0016e)

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.